Metal-Dependent Coordination Geometry Controls Autolytic Amide Bond Cleavage to Enable Prodrug Activation
Open Access
- 14 September 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 148 (38) , 41603-41611
Abstract
We introduce a peptide prodrug activation strategy that employs the trivalent Lewis-acidic metal ions Ga3+, Fe3+, In3+, and Co3+, chelated by triazacyclononanediacetic acid monoamides. The metal chelates trigger rate-tunable, metal-mediated, autolytic amide bond cleavage (TMAC) adjacent to N-methylated and canonical amino acids. Our studies reveal that the four TMAC-compatible metal ions induce amide bond hydrolysis with divergent pH dependence and mechanistic pathways. We subsequently linked Ga3+, Fe3+, In3+, and Co3+ complexes to the N-terminus of a potent cytotoxic cargo, monomethyl auristatin E (MMAE), to produce the proof-of-concept prodrug PD1. In vitro toxicity studies establish IC50 values in HeLa and PC-3 cells that broadly correlate with complex cleavage rates; the metal ion-free PD1 conjugate, the Zn-PD1 complex, as well as the Ga3+, Fe3+, In3+, and Co3+ chelate hydrolysis products alone confer no toxicity. Attachment of a cancer-targeting peptide to the metal chelate, furnishing PD2, enables targeted delivery of the therapeutic payload in vivo, compatible with noninvasive nuclear imaging using positron emission tomography with 68Ga or single-photon computed tomography with 111In. The corresponding natGa-PD2 complex selectively suppressed tumor growth in vivo with minimal off-target toxicity. These studies establish metal identity as a general design parameter for programming amide bond cleavage and introduce TMAC as a versatile platform to engender peptide prodrugs with tunable release kinetics.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (R01EB032349)
- Division of Chemistry (CHE-2017891)
This publication has 49 references indexed in Scilit:
- Linker Design for the Antibody Drug Conjugates: A Comprehensive ReviewChemMedChem, 2025
- Recent progress in the development of peptide-drug conjugates (PDCs) for cancer therapyEuropean Journal of Medicinal Chemistry, 2024
- Advances in acid-degradable and enzyme-cleavable linkers for drug deliveryCurrent Opinion in Chemical Biology, 2024
- Controlling the Redox Chemistry of Cobalt RadiopharmaceuticalsAngewandte Chemie International Edition, 2024
- Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugatesJournal of Controlled Release, 2024
- In vitro and in vivo evaluation of Bombesin-MMAE conjugates for targeted tumour therapyEuropean Journal of Medicinal Chemistry, 2024
- Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug releaseEuropean Journal of Medicinal Chemistry, 2024
- Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)Breast Cancer, 2020
- The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicityCancer Immunology, Immunotherapy, 2016
- Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenograftsInternational Journal of Cancer, 2015